Experimental Therapeutics Program (Project-003)

实验治疗计划（Project-003）

• 批准号: 9149894
• 负责人: John M Hoffman
• 金额: $ 7.79万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9149894
• 关键词: Abbreviations; Acceleration; Address; Antineoplastic Agents; Area; Basic Science; Biology; Cancer Center; Cancer Center Support Grant; Clinic; Clinical; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Conduct Clinical Trials; Cooperative Group Program; Development; Disease; Drug Delivery Systems; Drug Design; Drug usage; Ensure; Evaluation; Fostering; Funding; Generations; Genetic; Goals; Home environment; Human; Image; Institutes; Investigational Therapies; Laboratories; Lead; Leadership; Liquid substance; Malignant Neoplasms; Mission; Modeling; Multi-Institutional Clinical Trial; National Cancer Institute; National Clinical Trials Network; New Agents; Paper; Patient Care; Patients; Peer Review; Performance; Pharmaceutical Preparations; Pharmacy facility; Population; Publishing; Research; Research Personnel; Resources; Role; Science; Scientist; Source; Techniques; Therapeutic; Therapeutic Clinical Trial; Therapeutic Uses; Toxic effect; Translating; Translational Research; Translations; Treatment Efficacy; Treatment-Related Cancer; United States; United States National Institutes of Health; Universities; Utah; Work; abstracting; acronyms; assay development; base; bench to bedside; cancer cell; cancer therapy; cancer type; clinical care; college; computational chemistry; cost; design; drug development; drug discovery; experience; image guided; improved; in vivo Model; instructor; interdisciplinary collaboration; interest; medical schools; meetings; member; mid-career faculty; multidisciplinary; novel; novel strategies; novel therapeutics; patient oriented research; pre-clinical; professor; programs; screening; targeted delivery; targeted treatment

EXPERIMENTAL THERAPEUTICS PROGRAM ABSTRACT The Experimental Therapeutics (ET) Program of Huntsman Cancer Institute (HCI) is organized to facilitate transdisciplinary collaboration and to accelerate the progress of patient-oriented research to clinical translation and care of patients with cancer. The Program is organized into two main research themes: Drug Discovery/Drug Delivery and Clinical Research. Program members work to discover new agents that can be developed into drugs used to target cancer cells, develop second-generation polymeric carriers of anticancer drugs, design macromolecular targeted therapeutics with selective inhibitory effects on various types of malignancy, and develop drug-free macromolecular therapeutic constructs to increase efficacy of currently used therapeutics. Program members also ensure the execution of clinical research at HCI and the translation of important Cancer Center discoveries to human applications. Program members are also active in the leadership and conduct of clinical trials, including investigator-initiated trials. This clinical research focus aligns with the goals of NCI to develop and conduct state-of-the-art cancer treatment and advanced imaging multi- institutional clinical trials to evaluate new cancer therapies and related clinical approaches across a broad range of populations and cancer types. Program members are engaged in the effort to transform the previous NCI Clinical Trials Cooperative Group Program into a consolidated and integrated National Clinical Trials Network (NCTN), by providing clinical trials leadership and access to vitally important accruals among patients in the Intermountain West. The goals of the program are to: 1) provide new approaches to individualized cancer treatment as well as the most up-to-date clinical treatments via investigator-initiated therapeutic, imaging, and imaging-guided clinical trials; 2) foster bidirectional translation of discoveries between the laboratory and the clinic through collaborations and scientific synergy among ET program members, other program members, and HCI practicing clinicians; 3) develop novel therapies to meet unmet clinical needs in cancer through collaboration and interaction with the HCI multidisciplinary disease groups and disease-oriented research teams. The 39 ET Program members are drawn from 11 different University of Utah departments in the School of Medicine and Colleges of Pharmacy and Science. The Program includes 24 professors, seven associate professors, seven assistant professors, and one instructor, with 11 PhDs, 22 MDs, and six MD, PhDs. Funding includes $14.8M in 2013 total costs (NCI: 28%, other NIH: 20%, other peer-reviewed sources: 15%). From 2009–2013, ET members published 550 peer-reviewed papers, of which 28% involved collaboration with other Cancer Center members and 66% involved external partnerships.

实验治疗计划 抽象的 亨斯曼癌症研究所（HCI）的实验疗法（ET）计划是为了促进的 跨学科的合作，并加速以患者为导向的研究到临床翻译 和护理癌症患者。该计划组织为两个主要研究主题：药物 发现/药物输送和临床研究。计划成员努力发现可以是的新代理商 发展成用于靶向癌细胞的药物，发展抗癌的第二代聚合物载体 药物，设计大分子靶向疗法，对各种类型的抑制作用有选择性抑制作用 恶性肿瘤，并开发无药物的大分子热构建体，以提高当前的效率 二手疗法。计划成员还确保在HCI和翻译中执行临床研究 重要的癌症中心发现人类应用。计划成员也在活动中活跃 临床试验的领导和行为，包括研究人员发起的试验。该临床研究重点保持一致 NCI的目标是开发和进行最先进的癌症治疗和高级成像多 机构临床试验评估广泛的新癌症疗法和相关临床方法 种群和癌症类型的范围。计划成员正在努力改变以前的 NCI临床试验合作小组计划进入一个合并和综合的国家临床试验 网络（NCTN），通过提供临床试验的领导能力并获得患者的至关重要的范围 在西部的登国际。 该计划的目标是：1）为个性化癌症治疗提供新的方法 通过研究者引发的疗法，成像和成像引导的最新临床治疗 临床试验； 2）通过 ET计划成员，其他计划成员和HCI之间的合作和科学协同作用 实践临床医生； 3）开发新型疗法以通过协作满足癌症未满足的临床需求 并与HCI多学科疾病组和面向疾病的研究团队的互动。 39个ET计划成员来自学校的11个不同的犹他大学系 医学和药学和科学学院。该计划包括24名教授，七个同学 教授，七名助理教授和一名教练，拥有11名博士学位，22名MDS和6名MDS，博士学位。资金 在2013年的总成本中包括1480万美元（NCI：28％，NIH：20％，其他经过同行评审的来源：15％）。从 2009–2013，ET成员发表了550份同行评审的论文，其中28％涉及与其他合作 癌症中心成员和66％的人涉及外部伙伴关系。